Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is JSP Pharmaceutical Manufacturing (Thailand) PCL EBITDA Margin %?
JSP Pharmaceutical Manufacturing (Thailand) PCLBKK:JSP 80 EBITDA Margin % is 11.36% as of Mar. 2026, which is 31% below its 10-year median of 16.36. GuruFocus rates BKK:JSP with a GF Score™ of 80/100 and a GF Value™ of ฿3.16 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,957 Consumer Packaged Goods companies, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks better than 80.07% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JSP Pharmaceutical Manufacturing (Thailand) PCL EBITDA Margin % Related Terms
JSP Pharmaceutical Manufacturing (Thailand) PCL EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JSP Pharmaceutical Manufacturing (Thailand) PCL EBITDA Margin % vs Consumer Packaged Goods Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) has a EBITDA Margin % of 11.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. This is 31% below median its historical median of 16.36. Over the past decade, JSP Pharmaceutical Manufacturing (Thailand) PCL's EBITDA Margin % has ranged from 5.50 to 18.22. According to the industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #390 out of 1957 companies in the Consumer Packaged Goods industry, placing it in the top 19.9%.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL's EBITDA Margin % too high?
JSP Pharmaceutical Manufacturing (Thailand) PCL's current EBITDA Margin % of 11.36% is 31% below median its 10-year median of 16.36. Over the past 10 years, this metric has ranged from a low of 5.50 to a high of 18.22. The Consumer Packaged Goods industry median EBITDA Margin % is 9.00. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 11.36% is 26.2% above this industry median. Based on the distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #390 out of 1957 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, JSP Pharmaceutical Manufacturing (Thailand) PCL has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JSP Pharmaceutical Manufacturing (Thailand) PCL's EBITDA Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, JSP Pharmaceutical Manufacturing (Thailand) PCL ranks #390 out of 1957 companies for EBITDA Margin %. This places JSP Pharmaceutical Manufacturing (Thailand) PCL in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.00. JSP Pharmaceutical Manufacturing (Thailand) PCL's value of 11.36% is 26.2% above this benchmark. Historically, JSP Pharmaceutical Manufacturing (Thailand) PCL's own EBITDA Margin % has ranged from 5.50 to 18.22 over the past decade. While the company's 10-year median is 16.36 vs. the industry median of 9.00, JSP Pharmaceutical Manufacturing (Thailand) PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 9.00, based on 1,957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JSP Pharmaceutical Manufacturing (Thailand) PCL's current EBITDA Margin % of 11.36% is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JSP Pharmaceutical Manufacturing (Thailand) PCL and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JSP Pharmaceutical Manufacturing (Thailand) PCL's current EBITDA Margin % is 11.36%, which is 31% below median its own 10-year median of 16.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL stock overvalued right now?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿3.16, compared to a current price of ฿1.78 — trading 43.7% below its estimated fair value. The current EBITDA Margin % is 11.36%, which is 31% below median its 10-year median of 16.36 and 26.2% above the Consumer Packaged Goods industry median of 9.00. JSP Pharmaceutical Manufacturing (Thailand) PCL's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP), the current EBITDA Margin % is 11.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) Overvalued in 2026?
Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued.
The current stock price of ฿1.78 is trading 43.7% below its estimated GF Value™ of ฿3.16.
GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Significantly Undervalued.
Key valuation signals for BKK:JSP:
EBITDA Margin %: 11.36% (31% below median its 10-year median of 16.36)
GF Value™: ฿3.16 vs. price of ฿1.78 (43.7% below fair value)
Industry Position: 26.2% above the Consumer Packaged Goods median (#390 of 1957)
No single metric tells the full story. See the BKK:JSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
80GF Score
Get the complete analysis for BKK:JSP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:JSP has been successfully added to your 
